Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.
2.

A randomized trial of granulocyte colony-stimulating factor (Neupogen) starting day 1 vs day 7 post-autologous stem cell transplantation.

Bence-Bruckler I, Bredeson C, Atkins H, McDiarmid S, Hamelin L, Hopkins H, Perry G, Genest P, Huebsch L.

Bone Marrow Transplant. 1998 Nov;22(10):965-9.

3.

CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients.

Todisco E, Castagna L, Sarina B, Mazza R, Magagnoli M, Balzarotti M, Nozza A, Siracusano L, Timofeeva I, Anastasia A, Demarco M, Santoro A.

Eur J Haematol. 2007 Feb;78(2):111-6.

PMID:
17313558
4.

Retrospective comparison of neutropenia in children with Ewing sarcoma treated with chemotherapy and granulocyte colony-stimulating factor (G-CSF) or pegylated G-CSF.

Milano-Bausset E, Gaudart J, Rome A, Coze C, Gentet JC, Padovani L, Lacarelle B, André N.

Clin Ther. 2009;31 Pt 2:2388-95. doi: 10.1016/j.clinthera.2009.11.013.

PMID:
20110048
6.

A randomized, multicenter study of G-CSF starting on day +1 vs day +5 after autologous peripheral blood progenitor cell transplantation.

de Azevedo AM, Nucci M, Maiolino A, Vigorito AC, Simões BP, Aranha FJ, Tabak DG, Voltarelli J, de Souza CA.

Bone Marrow Transplant. 2002 May;29(9):745-51.

7.

Optimal timing (Preemptive versus supportive) of granulocyte colony-stimulating factor administration following high-dose cyclophosphamide.

Koumakis G, Vassilomanolakis M, Barbounis V, Hatzichristou E, Demiri S, Plataniotis G, Pamouktsoglou F, Efremidis AP.

Oncology. 1999;56(1):28-35.

PMID:
9885374
8.

The role of granulocyte colony-stimulating factor (filgrastim) in maintaining dose intensity during conventional-dose chemotherapy with ABVD in Hodgkin's disease.

Silvestri F, Fanin R, Velisig M, Barillari G, Virgolini L, Zaja F, Russo D, Baccarani M.

Tumori. 1994 Dec 31;80(6):453-8.

PMID:
7534963
9.

Peripheral blood stem cell mobilization by granulocyte colony-stimulating factor alone and engraftment kinetics following autologous transplantation in children and adolescents with solid tumor.

Watanabe H, Watanabe T, Suzuya H, Wakata Y, Kaneko M, Onishi T, Okamoto Y, Abe T, Kawano Y, Kagami S, Takaue Y.

Bone Marrow Transplant. 2006 Apr;37(7):661-8.

PMID:
16489358
11.

Individually determined dosing of filgrastim after autologous peripheral stem cell transplantation in patients with malignant lymphoma--results of a prospective multicentre controlled trial.

Faber E, Pytlík R, Slabý J, Zapletalová J, Kozák T, Raida L, Papajík T, Zikesová E, Maresová I, Hamouzová M, Indrák K, Trnený M.

Eur J Haematol. 2006 Dec;77(6):493-500. Epub 2006 Oct 17.

PMID:
17042769
12.

Early vs delayed administration of G-CSF following autologous peripheral blood stem cell transplantation.

Colby C, McAfee SL, Finkelstein DM, Spitzer TR.

Bone Marrow Transplant. 1998 May;21(10):1005-10.

13.

GM-CSF versus G-CSF: engraftment characteristics, resource utilization, and cost following autologous PBSC transplantation.

Zumberg MS, Leather HL, Nejame C, Meyer C, Wingard JR.

Cytotherapy. 2002;4(6):531-8.

PMID:
12568989
14.

Pegfilgrastim reduces the length of hospitalization and the time to engraftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with filgrastim.

Samaras P, Blickenstorfer M, Siciliano RD, Haile SR, Buset EM, Petrausch U, Mischo A, Honegger H, Schanz U, Stussi G, Stahel RA, Knuth A, Stenner-Liewen F, Renner C.

Ann Hematol. 2011 Jan;90(1):89-94. doi: 10.1007/s00277-010-1036-8. Epub 2010 Aug 13.

PMID:
20706722
15.

Marginal benefit/disadvantage of granulocyte colony-stimulating factor therapy after autologous blood stem cell transplantation in children: results of a prospective randomized trial. The Japanese Cooperative Study Group of PBSCT.

Kawano Y, Takaue Y, Mimaya J, Horikoshi Y, Watanabe T, Abe T, Shimizu Y, Matsushita T, Kikuta A, Watanabe A, Iwai A, Ito E, Endo M, Kodani N, Ohta S, Gushi K, Azuma H, Etoh T, Okamoto Y, Amano K, Hattori H, Eguchi H, Kuroda Y.

Blood. 1998 Dec 1;92(11):4040-6.

16.

[Prevention and treatment of febrile neutropenia].

Montemurro F, Gallicchio M, Aglietta M.

Tumori. 1997;83(2 Suppl):S15-9. Review. Italian.

PMID:
9235724
17.
18.

Optimal timing of G-CSF administration after CD34+ immunoselected peripheral blood progenitor cell transplantation.

Piccirillo N, Sica S, Laurenti L, Chiusolo P, La Barbera EO, Sorà F, Leone G.

Bone Marrow Transplant. 1999 Jun;23(12):1245-50.

20.

Use of granulocyte colony-stimulating factor after high-dose chemotherapy and autologous peripheral blood stem cell transplantation: what is the optimal timing?

Ener RA, Meglathery SB, Cuhaci B, Topolsky D, Styler MJ, Crilley P, Brodsky I, Kahn SB, King RS.

Am J Clin Oncol. 2001 Feb;24(1):19-25.

PMID:
11232944

Supplemental Content

Support Center